Bioprinting · 2025
LusoBioMaker: A low-cost 3D bioprinter with multi-extrusion and contour printing capabilities for thermo- and photocurable hydrogels towards complex tissue fabrication
3D bioprinting is an expanding field that allows for the design of intricate structures using multiple materials and living cells. This has enormous potential for applications in drug testing, regenerative medicine, and, more recently, cell-based food products, with the surge of the cellular agriculture field.
Performance the paper reports
3 of 5- Motion<50 µm positional errorMotion accuracy: reported
- Volume—Volumetric accuracy: not reported
- Viability97 %Cell viability: reported
- Unattended—Unattended operation: not reported
- StandardISO 230Standard compliance: reported
- Motion / positional accuracy<50 µm positional error
[curated] Abstract: "calibration and acceptance tests performed in accordance with the ISO 230-1/2 standards confirmed <50 µm positional error and <0.005° angular deviation across both extrusion nozzles".
- Cell viability97 %
[curated] Abstract: "maintaining 97 % L929 cell viability after fourteen days"; Results: "cell viability was maintained on day 14 (96 %, 97 %, 97 %) compared to day 7 (97 %, 97 %, 97 %)". The extractor had taken "5 % GelMA", an ink concentration.
- Reported against a written standardISO 230
Parallelism assessment: This test was performed following ISO 230–1:2012.
How hard this is to adopt
2.6 of 5, higher is easierEach score is shown against the range the other 59 builds actually occupy, because no criterion uses the full 1–5 scale. These describe how reproducible the build is, not how good the science is.
Resolution
3/1–5Smallest feature/positioning evidence about 250-330 µm.
Throughput
2/2–5Operation appears single-unit or manually constrained.
Parts sourcing
3/2–4Mix of common parts and custom/printed components.
Skill needed
2/2–4Multiple advanced technical skills appear required.
Facilities needed
2/2–4Requires specialized facilities, equipment, or consumables.
Documentation
3/2–5Some open documentation or files are available.
Validation effort
4/2–4Validation includes standards, benchmarking, replicates, or multi-condition tests.
Cycle time
2/1–4Cycle time appears slower.
2 further criteria are recorded but not shown
- Application Level — scored 4 (75% of records share one value), so it cannot separate one build from another.
- Build Time (scored for only 6 of 60 records), so it cannot separate one build from another.
Both remain in the published dataset.
Have you built this?
Report what it took, including attempts that stalled. A failed build tells the next laboratory what the documentation leaves out.
Know what this record is missing?
The index has no licence on the design files or link to the design files for this build. If you are an author or have built it, you know; a GitHub issue pre-filled with this record takes a minute.
Record metadata
Publication data
Matched by doi · retrieved 2026-07-21
Abstract
3D bioprinting is an expanding field that allows for the design of intricate structures using multiple materials and living cells. This has enormous potential for applications in drug testing, regenerative medicine, and, more recently, cell-based food products, with the surge of the cellular agriculture field. However, the high cost of equipment is frequently a significant limitation for implementing these approaches. Here, we present LusoBioMaker, an open-source bioprinter that delivers commercial-grade performance for under $900 of materi. Built on a modified Ender 3-V2 platform it integrates dual screw-driven extrusion, independent active temperature control (2–50 °C) and in-situ 365 nm photocuring, generating up to 320 N force through open-access firmware. Using κ-carrageenan, Pluronic F-127 and gelatin methacrylate/poly(ethyleneglycol) diacrylate (GelMA/PEGDA) inks we printed complex lattices with a printability factor of 0.995 and sub-millimetre dimensional errors while maintaining 97 % L929 cell viability after fourteen days. Comprehensive calibration and acceptance tests performed in accordance with the ISO 230-1/2 standards confirmed <50 μm positional error and <0.005° angular deviation across both extrusion nozzles. A systematic review of 17 reported low-cost bioprinters revealed that none combine dual screw extrusion, active thermal regulation and on-head UV curing in a single chassis, highlighting LusoBioMaker's unique features set. As a proof-of-concept, we bioprinted a hollow nipple–areola complex by co-extruding a thermosensitive κ-carrageenan core and a photocurable GelMA/PEGDA shell, exploiting all three hardware capabilities in one uninterrupted run. This demonstration underscores LusoBioMaker's capacity to manufacture anatomically intricate, gradient tissues on demand and to democratise advanced biofabrication workflows.
Bibliographic details
Access and metrics
Topics and keywords
Perspective and practical signals
Why it matters
No narrative note curated yet.
Limitations
No limitation note curated yet.